AI in Real-World Evidence: Insights from Mitch Higashi

By Staff Writer

August 7, 2025

In this update, we review the Q&A with Mitch Higashi, PhD, ISPOR’s Associate Chief Science Officer published on Pharmalive. It discusses AI in Real-World Evidence (RWE) and health technology assessments (HTA). Key themes include AI-driven early disease detection and NLP tackling unstructured clinical data. HTA bodies are evolving RWE methods for rare diseases, but barriers like data standardization remain. Higashi emphasizes augmented intelligence over autonomous AI. He also predicts quantum computing’s future role in RWE analytics.

Key Insights

Early detection algorithms use supervised learning to classify high-risk patients. They leverage diverse data types, reducing delayed diagnoses and costs. NLP processes unstructured EMR data (80% of healthcare data) to improve RWE research. HTA adoption is increasing as agencies use RWE for therapies with limited trial data, like gene therapies. They are developing external control arms and standardized methods. However, gaps in metadata standards hinder RWE integration. FAIR data principles (Findable, Accessible, Interoperable, Reusable) are prioritized to address this. Augmented intelligence should enhance clinician decision-making, not replace it. It provides real-time evidence synthesis while preserving patient-provider trust. Case studies show AI/ML in radiology and pathology optimizes image analysis. For example, it improves breast cancer screening efficiency by reducing false positives.

Implications

AI in Real-World Evidence could revolutionize clinical research efficiency, especially for rare diseases. However, data standardization is critical for interoperability and validity. ISPOR’s push for metadata frameworks will maintain trust in RWE-driven decisions. Quantum computing may analyze high-dimensional data in real time, enabling novel predictive models. This shift requires rethinking causal inference and patient categorization. Multidisciplinary collaboration will balance innovation with ethical rigor.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...